Vanderbilt University
PhD, 2009, Microbiology and Immunology

Case Western Reserve University
BA, 1999, Biology

Michael L. Vetter, PhD

Patent Agent

t 617-248-4746   f 617-248-4000

Dr. Michael Vetter has extensive scientific expertise in biology and immunology, honed by years of hands-on research.  He draws upon this robust technical background to deliver sophisticated counsel to biotechnology companies and research institutions, uniting a detail-oriented knowledge of clients’ technologies with a strategic understanding of their business goals.

Practice Focus

Intellectual Property:  assists in the preparation and prosecution of patent applications, freedom-to-operate analysis, due diligence reviews, and prior art, landscape and patentability analyses.

Previous Experience

As a Research Fellow at Harvard Medical School, Dr. Vetter examined host-viral pathogen interaction, with a focus on understanding the role of several different kinases in early post-entry and egress events of Dengue virus, and he was the recipient of the Virus-Host Interactions and Cancer Training Grant. 

Dr. Vetter completed his PhD studies at Vanderbilt University, where his research focused on investigating the effect of CD4+ T cell differentiation on the expression of the HIV restriction factor APOBEC3.  While at Vanderbilt, Dr. Vetter received the Cellular and Molecular Microbiology Training Grant, as well as the Conference on Retroviruses and Opportunistic Infections Young Investigator Award.  Prior to obtaining his PhD, Dr. Vetter was a Research Assistant at the Case Western Reserve University School of Medicine’s Division of Hypertension, where he investigated signaling of the second messenger cGMP.

Representative Engagements

  • Assists in preparing and prosecuting patent applications to support life sciences companies and research institutions.
  • Assists in due diligence and freedom to operate analysis for academic and industrial clients.
  • Conducts expert prior art and patent landscape searches.

Publications and Presentations

  • “Fluorescent Visualization of Src by Using Dasatinib-BODIPY,” first author, ChemBioChem, June 2014.
  • “Chemoproteomic Profiling Identifies Changes in DNA-PK as Markers of Early Dengue Virus Infection,” first author, ACS Chemical Biology, cover article December 2012.
  • “Cytoplasmic APOBEC3G in Activated T Helper Subtype Cells Restricts Incoming Vif-positive HIV-1,” first author, Journal of Virology, June 2009.
  • “Differences in APOBEC3G Expression in CD4+ T Helper Lymphocyte Subtypes Modulate HIV-1 Infectivity,” first author, PLOS Pathogens, February 2009.
  • “Cyclosporin A Disrupts Bradykinin Signaling Through Superoxide,” first author, Hypertension, April 2003.

Professional and Community Involvement

While a PhD student, Dr. Vetter served as an AIDS Outreach Coordinator in Nashville, where he organized and trained volunteers to educate students about HIV and AIDS and participated as a volunteer educator at local schools and in national video conferences.


Thank you for reaching out to contact Choate. Before you send your message, we wanted to make sure you are aware of the following. Please do not send any confidential information in response to this link. Sending an e-mail to Choate does not give rise to an attorney-client relationship, and will not be deemed to disqualify Choate from undertaking any engagement for a current or future client.  Before any attorney-client engagement may be formed, Choate will need to check for possible conflicts of interest, you will need to consider whether you wish to retain Choate as counsel, and we will need to consider whether we wish to accept the potential engagement. In the meantime, Choate reserves the right to represent parties with interests adverse to you.